Sökning: onr:"swepub:oai:gup.ub.gu.se/135557" >
The effect of orlis...
The effect of orlistat 60 mg on changes in body composition over a 24 week treatment: a randomized, placebo-controlled, multicenter study
-
Smith, SR (författare)
-
- Stenlöf, Kaj, 1965 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för klinisk prövning och entreprenörskap,Institute of Medicine, Department of Clinical Trials and Entrepreneurship
-
Greenway, F (författare)
-
visa fler...
-
McHutchison, J (författare)
-
Savastano, D (författare)
-
Bansal-Dev, V (författare)
-
Schwartz, S (författare)
-
visa färre...
-
(creator_code:org_t)
- 2010
- 2010
- Engelska.
-
Ingår i: Obesity Reviews (Poster presentations). - 1467-7881. ; 11:Supplement s1
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- Introduction: A paucity of data exists on the effects of 60 mg orlistat on changes in body composition, particularly visceral adipose tissue (VAT). Methods: Overweight and obese adults (BMI 25–34.9) with a waist circumference >88 cm (women) or >102 cm (men) were randomized to either orlistat 60 mg (n = 61) or placebo (n = 62) tid for 6 months to examine changes in body composition. Subjects were encouraged to maintain a hypocaloric (-500 kcals/day), low fat (30% calories from fat) diet and were encouraged to exercise. Change from baseline for VAT (kg) by CT was examined at 12 and 24 weeks by ANCOVA. Change from baseline in total fat mass (FM) by EchoMRI, body weight, and waist circumference were examined across multiple time points beginning at week 2 using repeated measure analysis. Results: Mean changes from baseline for all variables were significant in both groups. VAT reduction was greater with orlistat compared to placebo at 12 (LS mean ± SE; )0.50 ± 0.06 vs. )0.32 ± 0.06, P < 0.05) and 24 weeks ()0.62 ± 0.08 vs. )0.32 ± 0.08 P < 0.01). A significantly greater reduction was observed over the 24 weeks in the orlistat group for FM and body weight, as compared to placebo (Group effect P < 0.05), but not waist circumference. Conclusion: Orlistat 60 mg provided significantly greater reductions in weight, FM and VAT across 24 weeks, compared to placebo. The reductions in VAT were relatively stable from 12 to 24 weeks in placebo subjects, whereas VAT reduction in orlistat-treated subjects continued over the 24 week duration.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- kon (ämneskategori)
Hitta via bibliotek
Till lärosätets databas